The Alliance for the Adoption of Innovations in Medicine (Aimed Alliance) believes Americans are better served through policies that define the value of new therapies in patient terms, not upfront costs. This means assessing novel therapies on the basis of improved longevity, productivity, and quality of life where the payoff can be substantial.
Given that restricting access harms patients, 15 states and the District of Columbia are taking action, including Delaware, Maryland, and Louisiana, which passed laws capping co-pays on specialty medicines. Yet, if the real value of novel therapies is to be realized, we need more patient protections at the state and federal levels. Instead of a petition to impose more cost containment policies, now is the time for a petition to increase patient access to novel therapies through legislative and regulatory remedies.
Read more...
No comments:
Post a Comment